phrykt

Utah Medical Products Inc (UTMD): who owns it and who trades it

As of Nov 16, 2026, UTMD insiders reported 1 purchase worth $66.8K in the last 12 months. The largest buyer was Kevin L Cornwell (CEO), with $66.8K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Utah Medical Products

From the latest filings

Overall: more buying than selling. Insiders mostly bought. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns UTMD

114 funds and institutions reported UTMD shares worth $161M at the end of Q2 2026, about 73% of the company. The largest holder is Brandes Investment Partners, LP with 14.9%.

Funds and institutions (13F) 73%Everyone else 27%

10 largest owners, by share of the company

Brandes Investment Partners, LP14.9%
BlackRock, Inc.6.4%
Dimensional Fund Advisors LP6.2%
Renaissance Technologies LLC5.5%
Vanguard Capital Management LLC4.2%
Geode Capital Management, LLC3.4%
Minerva Advisors LLC2.9%
Hotchkis & Wiley Capital Management LLC2.7%
Rice Hall James & Associates, LLC2.2%
Morgan Stanley2.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Brandes Investment Partners, LP475,15814.92%$32.8M+6%
BlackRock, Inc.203,6906.40%$14.1M+9%
Dimensional Fund Advisors LP198,8176.24%$13.7M+0%
Renaissance Technologies LLC175,8145.52%$12.1M-5%
Vanguard Capital Management LLC134,5354.22%$9.3M-3%
Geode Capital Management, LLC108,0483.39%$7.5M-10%
Minerva Advisors LLC93,6152.94%$6.5MNo change
Hotchkis & Wiley Capital Management LLC85,2312.68%$5.9M-4%
Rice Hall James & Associates, LLC71,3632.24%$4.9M+5%
Morgan Stanley69,6712.19%$4.8M+43%
State Street Corp63,9372.01%$4.4M-1%
Quantinno Capital Management LP43,0741.35%$3M+44%
UBS Group AG34,3691.08%$2.4M-7%
Bank of New York Mellon Corp34,2631.08%$2.4M+7%
Northern Trust Corp30,1040.95%$2.1M-1%
Huber Capital Management LLC29,0090.91%$2M-19%
Cardinal Capital Management27,0940.85%$1.9M+2%
Everett Harris & Co23,9330.75%$1.7M-6%
T. Rowe Price Associates21,9380.69%$1.5M+20%
O'shaughnessy Asset Management, LLC21,6830.68%$1.5M+2%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, UTMD insiders reported $66.8K of open-market purchases and $0 of sales.

Purchases, 12 months
$66.8K
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Oct 29, 2026
Filed Oct 29, 2026

Purchases and sales by month

$66.8K$66.8KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 29, 2026Kevin L CornwellCEOPurchase1,000$66.75$66.8KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Kevin L CornwellChairman, CEO, Director$66.8K–Oct 29, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

UTMD short interest

Low short interest. 4.8% of UTMD shares are sold short: about 1 share in 21. Over the last 12 reports the number of shares short went up 14%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 151,293 UTMD shares were sold short, 4.8% of the shares outstanding, up 7.9% from the report before. At the average daily volume of 38,807 shares, buying them all back would take about 3.9 trading days (days to cover).

Shares short, % of all shares

4.75%May 15Oct 305.69%

Days to cover

3.9May 15Oct 3017.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026151,2934.75%+8%38,8073.9
Oct 15, 2026140,2154.40%-8%39,1233.6
Sep 30, 2026151,9124.77%-12%31,6904.8
Sep 15, 2026172,1805.41%+3%38,0254.5
Aug 31, 2026166,8055.24%+19%41,4414.0
Aug 14, 2026139,7154.39%+3%19,8577.0
Jul 31, 2026135,5794.26%-3%40,2203.4
Jul 15, 2026140,0864.40%+1%18,1557.7
Jun 30, 2026138,6964.35%+6%20,4186.8
Jun 15, 2026131,1334.12%+16%8,58815.3
May 29, 2026113,0143.55%-15%11,9899.4
May 15, 2026132,6724.17%+5%8,62015.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Utah Medical Products company events

Utah Medical Products filed 7 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 3, 2026.

  1. Nov 3, 2026AnnouncementUtah Medical Products, Inc. announced that it is increasing its regular quarterly cash dividend. Filing
  2. Oct 22, 2026ResultsReleased financial results. Filing
  3. Aug 31, 2026AnnouncementShared information with investors. Filing
  4. Jul 23, 2026ResultsReleased financial results. Filing
  5. May 4, 2026VoteReported shareholder vote results. Filing
  6. Apr 23, 2026ResultsReleased financial results. Filing
  7. Jan 29, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Utah Medical Products financials

Famous investors that hold UTMD

2 of the 50 well-known investors we track reported holding UTMD in their latest 13F filing. The largest position is Jim Simons's, worth $12.4M.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026167,514$12.4M0.0%-5%
Ken Griffin · Citadel AdvisorsQ3 202613,904$1M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Utah Medical Products Inc (UTMD) stock

Who owns the most UTMD stock?

The largest reported owner of Utah Medical Products Inc (UTMD) is Brandes Investment Partners, LP, with 14.9% of the company. In total, 114 funds and institutions reported holding UTMD at the end of Q2 2026, together about 73% of the shares. See the largest owners.

Are UTMD insiders buying or selling?

In the last 12 months, UTMD insiders reported 1 open-market purchase worth $66.8K and no sales. The latest trade was on Oct 29, 2026. See every trade.

What is the short interest in UTMD?

As of Oct 30, 2026, 151,293 UTMD shares were sold short, 4.8% of the shares outstanding, up 7.9% from the report before. At the average daily volume of 38,807 shares, buying them all back would take about 3.9 trading days (days to cover). See the history.

Which famous investors hold UTMD?

2 of the 50 well-known investors we track reported UTMD in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $12.4M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.